Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (12189)	7/5/2013 8:58:48 PM
From: Jack Russell	Respond to of 13111

You know those guys who write the peer stuff are not only wrong a lot of the time, but they Plagiarize things also.... Simple Stuff....

To: Mimbari who wrote (12189)	7/8/2013 6:51:22 AM
From: NTTG	2 Recommendations Recommended By boomertree2 Pogeu Mahone Read Replies (1) \| Respond to of 13111

My kind...LOL. Let s just leave the point as you stated it...you really dont have a background in this area and can not read the data with an open mind or 'benchmarking' perspective. Your views largely reflect parroting of third hand opinion and PVCT mouth-piece functions. I know you dont know a drug that has launched with no publications, no one does, no one takes that approach...in fact, the move in oncology over the past few years is to 'sync' presentations of major study results at meetings such as ASCO with same month or same week publication of the results in peer reviewed journals. An impressive trend for an industry that doesn't care about publishing. The industry does abhor poorly designed studies published in trivial journals, regardless of whether the study is run by a clinical investigator trying to get research money and clinical advancement or academic investors trying to get grants and academic advancement..either way, the key is the poorly designed studies. Imagine how bad a study must be to not be published at all? Or can not be presented at a major dermatology meeting as an abstract? The list you provide is non-descrip and frankly un-impressive for a company that has tried to start a Breast cancer, MM, HHC and 'other' cancer research programs over the years. Clearly if the company has gotten input from these 'opinion for hire folks' they have not acted well on the advice. The notion that they included staff and techs at study sights is laughable...I wonder how many employes Pfizer would have if they included all the individuals at all their study sites? The key is performance...PVCT has apparently paid out a lot of money over the years to friends and pals (take a look at the PI for the HCC phase I trial, and check the BOD list), but have executed poorly on the advice I am glad you are investing here, more money in the pool is always a good thing..